RECRUITING

Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this research study is to compare the proportion of wound closure in subjects that receive E-GRAFT™ with SOC versus FIBRACOL™ with SOC. Other research purposes include the following: * Rate of wound closure * Change in ulcer size over 12 weeks * Any adverse events or reactions (side effects) * Change in pain levels * Occurrence of infection

Official Title

A Randomized Controlled Clinical Trial Evaluating The Efficacy of an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone

Quick Facts

Study Start:2024-12-28

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06764953

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subjects must be at least 18 years of age or older. 2. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with manual measure. 3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit. 4. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 5. The subject must consent to using the prescribed off-loading method for the duration of the study. 6. The subject must agree to attend the weekly study visits required by the protocol. 7. The subject must be willing and able to participate in the informed consent process. 8. The target ulcer must be full thickness on the foot or leg that does not probe to bone. 9. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit: 1. TCOM ≥30 mmHg 2. ABI between 0.7 and 1.3 3. PVR: Biphasic 4. TBI ˃0.6 5. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle 10. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 11. Target ulcers must have been treated with compression therapy for at least 14 days prior to randomization.	1. A subject known to have a life expectancy of \< 6 months is excluded. 2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded. 3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence. 4. Index ulcer and/or index ulcer limb may have had prior infection(s), but infection(s) must be adequately treated and controlled 5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded. 6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted. 7. A subject with a previous partial amputation on the affected leg is excluded if the resulting deformity impedes proper offloading of the target ulcer. 8. If a subject is diabetic and has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded. 9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded. 10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC. 11. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded. 12. A potential subject with end stage renal disease requiring dialysis is excluded. 13. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded. 14. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded

Inclusion Criteria

Exclusion Criteria

1. Subjects must be at least 18 years of age or older.
2. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with manual measure.
3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
4. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
5. The subject must consent to using the prescribed off-loading method for the duration of the study.
6. The subject must agree to attend the weekly study visits required by the protocol.
7. The subject must be willing and able to participate in the informed consent process.
8. The target ulcer must be full thickness on the foot or leg that does not probe to bone.
9. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:
1. TCOM ≥30 mmHg
2. ABI between 0.7 and 1.3
3. PVR: Biphasic
4. TBI ˃0.6
5. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle
10. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
11. Target ulcers must have been treated with compression therapy for at least 14 days prior to randomization.

1. A subject known to have a life expectancy of \< 6 months is excluded.
2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded.
3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
4. Index ulcer and/or index ulcer limb may have had prior infection(s), but infection(s) must be adequately treated and controlled
5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded.
6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted.
7. A subject with a previous partial amputation on the affected leg is excluded if the resulting deformity impedes proper offloading of the target ulcer.
8. If a subject is diabetic and has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded.
9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded.
10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC.
11. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
12. A potential subject with end stage renal disease requiring dialysis is excluded.
13. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded.
14. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded

Contacts and Locations

Study Contact

Adam Isaac, DPM

CONTACT

(301) 471-8378

aisaacdpm@gmail.com

Melissa Crosswhite

CONTACT

Mcrosswhite@periedu.com

Principal Investigator

Charles M Zelen, DPM FACFAS

PRINCIPAL_INVESTIGATOR

Professional Education and Research Institute

Study Locations (Sites)

Professional Education and Research Institute

Roanoke, Virginia, 24016

United States

Collaborators and Investigators

Sponsor: Skye Biologics Holdings, LLC

Charles M Zelen, DPM FACFAS, PRINCIPAL_INVESTIGATOR, Professional Education and Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-28

Study Completion Date2025-12

Study Record Updates

Study Start Date2024-12-28

Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

Venous Leg Ulcers